PROFILE VIEW

Sanofi Genzyme

Manufacturer

As the specialty care global business unit of Sanofi, we are focused on rare diseases, rare blood disorders, multiple sclerosis, oncology and immunology. More than 30 years since we began, we remain just as committed to and passionate about advancing therapies that offer hope to patients and families. Our approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, we rapidly grew to become one of the world’s leading biotechnology companies, recognized for our pioneering development of treatments for rare genetic disorders and our innovative contributions to medical science and biomanufacturing. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofi’s programs in oncology and immunology. In 2018, with the acquisitions of Bioverativ and Ablynx, we further expanded our focus to include rare blood disorders, bringing deep expertise in hematology. Spirit of Hope - A History of Genzyme 1981-2012 As a pioneer of the biotechnology movement in the early 1980s, Genzyme has always been driven by cutting-edge science and a commitment to developing treatments for unmet medical needs. In this video, former CEO David Meeker, former CEO Henri Termeer, and patients share how Genzyme has continued to build on this foundation over the past three decades. Our ambition is to be the industry leader in specialty care. We currently provide more than 25 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi laboratories. Driven by our commitment to patients, we strive to develop strong relationships with our patient communities, listening to their perspectives so that we can truly understand their needs. These collaborations continue to guide and motivate us as we work to push the boundaries of medicine and technology to develop new and better therapies where none existed before.

Contact Information

17 252-75-00

50 Binney Street, Cambridge, MA 02142, США

Products

- - - - - - - - - - - - - - - - - - - - - -
Product type Brand name Content Dosage form Medical Classification

Finished Product

ALDURAZYME Laronidase 2.9 mg Solution 5 mL VIAL

Finished Product

AUBAGIO® Teriflunomide 7 mg Tablet, film coated 28 BLPK

Finished Product

CAPRELSA® Vandetanib 100 mg Tablet 30 BLPK

Finished Product

CAPRELSA® Vandetanib 300 mg Tablet 30 BLPK

Finished Product

Cerdelga® Eliglustat 84 mg Capsule 56 BLPK

Finished Product

Cerezyme® Imiglucerase 400 [iU] Injection 10 mL VIAL

Finished Product

Clolar® Clofarabine 20 mg Injection 20 mL VIAL

Finished Product

ELITEK® Rasburicase 1.5 mg Injection, powder, lyophilized, for solution 1.5 mg VIALSD

Finished Product

ELITEK® Rasburicase 7.5 mg Injection, powder, lyophilized, for solution 7.5 mg VIALSD

Finished Product

ELOXATIN® Oxaliplatin 5 mg Injection, powder, for solution 50 mg VIALSU

Finished Product

ELOXATIN® Oxaliplatin 5 mg Injection, powder, for solution 100 mg VIALSU

Finished Product

Fabrazyme® Agalsidase beta 5 mg Injection, powder, lyophilized, for solution 5 mg VIALSD

Finished Product

Fabrazyme® Agalsidase beta 35 mg Injection, powder, lyophilized, for solution 35 mg VIALSD

Finished Product

JEVTANA® Cabazitaxel 60 mg Injection, solution 1.5 mL VIALSD

Finished Product

LEMTRADA® Alemtuzumab 12 mg Injection, solution, concentrate 1.2 mL VIALSD

Finished Product

Lumizyme® Alglucosidase alfa 50 mg Injection, powder, lyophilized, for solution 50 mg VIALSU

Finished Product

MOZOBIL® Plerixafor 20 mg Injection, solution 1.2 mL VIALSU

Finished Product

TAXOTERE® Docetaxel 20 mg Injection 1 mL VIALSU

Finished Product

TAXOTERE® Docetaxel 80 mg Injection 4 mL VIALSU

Finished Product

Thymoglobulin® Antithymocyte immunoglobulin (rabbit) 25 mg Injection, powder, lyophilized, for solution 10 mL 1 VIALSU

Finished Product

Thyrogen® Thyrotropin alfa 0.9 mg Injection, powder, lyophilized, for solution 1 VIALSU

Finished Product

ZALTRAP® Aflibercept 100 mg Injection, solution 4 mL 1 VIALSU